Know Cancer

or
forgot password

Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)


N/A
18 Years
N/A
Not Enrolling
Both
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor

Thank you

Trial Information

Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)


OBJECTIVES:

- To establish a DNA bank from donor and recipient (prior to transplant) peripheral blood
for SNP studies.

- To establish a tissue bank for gene expression studies using donor and recipient
(post-transplant) peripheral blood samples.

- To establish a tissue bank for proteomic studies using donor and recipient blood and
urine samples.

- To establish a tissue bank for various studies using biopsy specimens.

- To establish a tissue bank for flow cytometric studies using recipient
(post-transplant), and sample from stem cell product.

OUTLINE: Peripheral blood samples are collected from donors prior to stem cell mobilization
and from patients prior to starting preparative regimen. Samples are studied by single
nucleotide polymorphism (SNP) analysis, SNP array, proteomic analysis, gene expression, and
other immunological laboratory methods. Blood, urine, and tissue samples are preserved for
future studies. Extra skin biopsies and gastrointestinal biopsies are performed at diagnosis
of graft-vs-host disease and preserved in a tissue bank for flow cytometric studies.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Approved for allogeneic stem cell transplantation

- Sample of the stem cells from donor must meet 1 of the following criteria:

- Total peripheral blood stem cell dose > 5 X10^6 CD34+ cells/kg

- Marrow cell dose > 3 X 10^8 nucleated cells/kg

PATIENT CHARACTERISTICS:

- Platelet count > 50,000/mm³ (for patients undergoing endoscopic biopsies)

- INR < 1.5 (for patients undergoing endoscopic biopsies)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

DNA bank from donor and recipient (prior to transplant) peripheral blood for single nucleotide polymorphism studies

Outcome Time Frame:

Completion of transplant

Safety Issue:

No

Principal Investigator

Madan Jagasia, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center

Authority:

United States: Federal Government

Study ID:

VICC BMT 0664

NCT ID:

NCT00900406

Start Date:

January 2007

Completion Date:

March 2010

Related Keywords:

  • Breast Cancer
  • Chronic Myeloproliferative Disorders
  • Gestational Trophoblastic Tumor
  • Graft Versus Host Disease
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Neuroblastoma
  • Ovarian Cancer
  • Testicular Germ Cell Tumor
  • Breast Neoplasms
  • Neoplasms
  • Graft vs Host Disease
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Neuroblastoma
  • Ovarian Neoplasms
  • Trophoblastic Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Gestational Trophoblastic Neoplasms
  • Myelodysplastic-Myeloproliferative Diseases

Name

Location

Vanderbilt-Ingram Cancer CenterNashville, Tennessee  37232-6838
Vanderbilt-Ingram Cancer Center - Cool SpringsNashville, Tennessee  37064
Vanderbilt-Ingram Cancer Center at FranklinNashville, Tennessee  37064